Claims for Patent: 12,161,761

Summary for Patent: 12,161,761

Title:	Extended release multiparticulates of ranolazine
Abstract:	The present invention relates to an extended release multiparticulate composition comprising a plurality of discrete units, each discrete unit comprising ranolazine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The said multiparticulate composition is sprinkled onto soft foods or liquids for oral administration. Further, the multiparticulate composition is bioequivalent to the marketed extended release tablet. It further relates to a process of preparation of said multiparticulate composition and method of treatment of patients suffering from angina by administering said composition.
Inventor(s):	Harinder Singh, Shavej AHMAD, Romi B. Singh
Assignee:	Sun Pharmaceutical Industries Ltd
Application Number:	US17/972,435
Patent Claims:	1. An extended release multiparticulate composition comprising a plurality of discrete units, each discrete unit comprising: a) a drug core comprising ranolazine and one or more pharmaceutically acceptable excipients; b) an extended release coating over the drug core; wherein the composition is filled into a capsule or a sachet and the composition comprises about 1000 mg of ranolazine; wherein ranolazine is present in an amount of about 40% to about 85% by weight of the multiparticulate composition; wherein extended release coated cores have d90 particle size range from about 0.35 mm to about 0.90 mm determined using a Malvern particle size analyzer; wherein said multiparticulate composition releases: about 60% to about 90% of the ranolazine in 6 hours in 900 mL pH 6.8 phosphate buffer. 2. The composition according to claim 1, where the release of ranolazine is measure in United States Pharmacopoeia (USP) type II dissolution apparatus, rotated at 50 rpm at a temperature of 37° C. 3. An extended release multiparticulate composition comprising a plurality of discrete units, each discrete unit comprising: a) a drug core comprising ranolazine and one or more pharmaceutically acceptable excipients; b) an extended release coating over the drug core; wherein the composition is filled into a capsule or a sachet and the composition comprises about 1000 mg of ranolazine; wherein ranolazine is present in an amount of about 40% to about 85% by weight of the multiparticulate composition; wherein on administration to healthy subjects under fed conditions provide a mean Cmax value in the range of about 1 to about 5 ng/ml/mg and a mean AUC0-t value in the range of about 12 to about 53 ng·hr/mL/mg. 4. The extended release multiparticulate composition according to claim 3, wherein the multiparticulate composition when administered to healthy subjects under fasting conditions provide a mean Cmax value in the range of about 0.9 to about 2.9 ng/ml/mg. 5. The extended release multiparticulate composition according to claim 3, wherein the multiparticulate composition when administered to healthy subjects under fasting conditions provide a mean AUC0-t value in the range of about 14.7 to about 50 ng·hr/mL/mg. 6. The extended release multiparticulate composition of claim 1, wherein said discrete units are in a form selected from the group consisting of pellets, granules, mini-tablets and beads. 7. The extended release multiparticulate composition of claim 1, wherein the extended release coating comprises water-insoluble polymer selected from the group comprising of cellulose esters, polymethacrylic acid ester co-polymers, aminoalkyl methacrylate copolymers, a co-polymer of polyvinyl acetate and polyvinyl-pyrrolidone, and mixture thereof. 8. The extended release multiparticulate composition of claim 1, wherein the extended release coating comprises pH-dependent polymer selected from the group comprising of methyl acrylate acrylic acid copolymer, methyl acrylate methacrylic acid copolymer, butyl acrylate styrene acrylic acid copolymer, methacrylic acid methyl methacrylate copolymer, methacrylic acid ethyl acrylate copolymer methyl acrylate methacrylic acid octyl acrylate copolymer; hydroxypropylmethylcellulose acetate succinate, hydroxypropylmethylcellulose phthalate, hydroxymethylethylcellulose phthalate, cellulose acetate phthalate, cellulose acetate succinate, cellulose acetate maleate, cellulose acetate trimelliate cellulose benzoate phthalate, cellulose propionate phthalate, methylcellulose phthalate, carboxymethylethylcellulose, ethylhydroxyethylcellulose phthalate, polyvinyl alcohol phthalate, polyvinylacetal phthalate, polyvinyl butylate phthalate, polyvinylacetoacetal phthalate, maleic acid copolymers and mixtures thereof. 9. The extended release multiparticulate composition of claim 1, wherein the extended release coating layer further comprises a plasticizer selected from the group consisting of acetyl tributyl citrate, acetyl triethyl citrate, dibutyl sebacate, diethyl phthalate, castor oil, diacetylated monoglycerides, triacetin, tributyl citrate, triethyl citrate and mixtures thereof. 10. The extended release multiparticulate composition of claim 1, wherein the discrete units further comprise a top layer. 11. An extended release multiparticulate sprinkle composition comprising a plurality of discrete units, each discrete unit comprising: a) a core comprising ranolazine and one or more pharmaceutically acceptable excipients; b) an extended release coating over the core and wherein extended release coated cores have d90 particle size range from about 0.35 mm to about 0.90 mm determined using a Malvern particle size analyzer, and wherein ranolazine is present in an amount of about 40% to about 85% by weight of the multiparticulate composition; wherein the amount of discrete units filled in a sachet or capsule can range from about 1.2 g to about 3.0 g of ranolazine. 12. The extended release multiparticulate composition of claim 3, wherein said discrete units are in a form selected from the group consisting of pellets, granules, mini-tablets and beads. 13. The extended release multiparticulate composition of claim 3, wherein the extended release coating comprises water-insoluble polymer selected from the group comprising of cellulose esters, polymethacrylic acid ester co-polymers, aminoalkyl methacrylate copolymers, a co-polymer of polyvinyl acetate and polyvinyl-pyrrolidone, and mixture thereof. 14. The extended release multiparticulate composition of claim 3, wherein the extended release coating comprises pH-dependent polymer selected from the group comprising of methyl acrylate acrylic acid copolymer, methyl acrylate methacrylic acid copolymer, butyl acrylate styrene acrylic acid copolymer, methacrylic acid methyl methacrylate copolymer, methacrylic acid ethyl acrylate copolymer methyl acrylate methacrylic acid octyl acrylate copolymer; hydroxypropylmethylcellulose acetate succinate, hydroxypropylmethylcellulose phthalate, hydroxymethylethylcellulose phthalate, cellulose acetate phthalate, cellulose acetate succinate, cellulose acetate maleate, cellulose acetate trimelliate cellulose benzoate phthalate, cellulose propionate phthalate, methylcellulose phthalate, carboxymethylethylcellulose, ethylhydroxyethylcellulose phthalate, polyvinyl alcohol phthalate, polyvinylacetal phthalate, polyvinyl butylate phthalate, polyvinylacetoacetal phthalate, maleic acid copolymers and mixtures thereof. 15. The extended release multiparticulate composition of claim 3, wherein the extended release coating layer further comprises a plasticizer selected from the group consisting of acetyl tributyl citrate, acetyl triethyl citrate, dibutyl sebacate, diethyl phthalate, castor oil, diacetylated monoglycerides, triacetin, tributyl citrate, triethyl citrate and mixtures thereof. 16. The extended release multiparticulate composition of claim 3, wherein the discrete units further comprise a top layer.